Skip to main content
Science Catalogs
Health Sciences

Daraxonrasib plus chemotherapy shrinks tumours in first-line metastatic pancreatic cancer

Combining the oral RAS inhibitor daraxonrasib with standard chemotherapy shrank tumours in around six in ten previously untreated patients with metastatic pancreatic cancer, according to updated phase I/II results. Median progression-free survival was 12.8 months, well beyond the five to six months typically seen with chemotherapy alone. The data come from the RMC-GI-102 trial and were presented at the 38th EORTC-NCI-AACR Symposium in Barcelona by Dr Wungki Park of Memorial Sloan Kettering Cancer Center.

Trial design and results

As of 28 September 2026, 61 patients had received the combination as first-line therapy. Participants took 200 mg of daraxonrasib by mouth each day. They also received intravenous gemcitabine (1,000 mg/m²) and nab-paclitaxel (125 mg/m²) on days 1 and 15 of each treatment cycle. Median follow-up was 18.3 months, with a range of 13.1 to 23.7 months.

  • Objective response rate: 60.7%, including complete responses in 8.2% of patients, whose tumours were no longer detectable.
  • Disease control rate: 90.2%.
  • Median progression-free survival: 12.8 months.
  • Overall survival at 12 months: 76.6%.

For context, the investigators note that chemotherapy alone shrinks tumours in 23% to 42% of patients, and median survival is 8 to 11 months. Only 3% of patients are alive five years after diagnosis.

Why RAS matters

More than 90% of pancreatic cancers carry a mutation in the RAS gene. The mutation locks the protein in an active state, so cells receive a constant signal to divide. RAS was long considered very hard to target with drugs. Daraxonrasib is designed to block the active form of the protein, known as RAS(ON), and so cut off the signalling on which the tumour cells depend.

Safety

The most common adverse events were rash, diarrhoea and fatigue, along with chemotherapy-related effects such as reduced blood cell counts. The investigators report that these were managed with standard medical care. Stopping treatment because of daraxonrasib-related side effects was uncommon, occurring in 5% of patients.

Limitations and next steps

The main caveat is the design. This is an early-phase study without a comparison group, so the outcomes cannot be attributed to the combination with certainty. Park described the findings as needing careful interpretation, and the comparisons with historical chemotherapy figures are indirect. Patient numbers are also modest.

A definitive test is under way in the global phase 3 RASolute-303 trial, of which Park is principal investigator. It compares daraxonrasib alone, and daraxonrasib with gemcitabine and nab-paclitaxel, against chemotherapy alone.

Elena Garralda, chair of the symposium and co-director of the clinical research programme at the Vall d'Hebron Institute of Oncology, was not involved in the work. She noted that several studies at the meeting suggest RAS mutations can now be targeted. She also highlighted that RAS inhibitors can be combined with existing treatments and given at the start of therapy for advanced disease.

Wider relevance

RAS mutations also drive some lung, bowel, biliary tract, appendiceal and gynaecological cancers. Whether daraxonrasib plus chemotherapy helps in those settings would require separate trials. For researchers, the results strengthen the case for RAS(ON) inhibition as a treatment strategy. The randomised phase 3 data will show whether the early response and disease-control signals translate into survival benefit.

Source: Metastatic pancreatic cancer responds well to treatment with combination of daraxonrasib and chemotherapy (Medical Xpress, 21 November 2026).

Image: AI-generated illustration.

Working on this topic? Find a journal for your research or join the discussion on Scholars Post.